

III

(Notices)

COMMISSION

Calls for proposals for indirect RTD actions under the specific programme for research, technological development and demonstration: 'Integrating and strengthening the European Research Area'**Thematic priority area 'Life sciences, genomics and biotechnology for health'****Call identifiers: FP6-2005-LIFESCIHEALTH-6, FP6-2005-LIFESCIHEALTH-7**

(2005/C 168/15)

1. In accordance with Decision No 1513/2002/EC of the European Parliament and of the Council, of 27 June 2002, concerning the sixth framework programme of the European Community for research, technological development and demonstration activities contributing to the creation of the European Research Area and to innovation (2002 to 2006) ⁽¹⁾, the Council adopted on 30 September 2002 the specific programme for research, technological development and demonstration: 'Integrating and strengthening the European Research Area' (2002-2006) ⁽²⁾ (referred to as 'the specific programme').
2. The present calls for proposals for indirect RTD actions (referred to as 'the calls') comprises the present general part and the specific conditions that are described in the annexes. The annexes indicate in particular, the dates of closure for the submission of proposals for indirect RTD actions, an indicative date for the completion of the evaluations, the indicative budget, the instruments and the areas concerned, the evaluation criteria for the evaluation of proposals for indirect RTD actions, the minimum number of participants, and any applicable restrictions.

In accordance with Article 5(1) of the specific programme, the Commission of the European Communities (referred to as 'the Commission') has adopted on 9 December 2002 a work programme ⁽³⁾ (referred to as 'the work programme') setting out in greater detail the objectives and scientific and technological priorities of the specific programme, and the timetable for implementation.

In accordance with Article 9(1) of the Regulation of the European Parliament and of the Council, of 16 December 2002, concerning the rules for the participation of undertakings, research centres and universities in, and for the dissemination of research results for, the implementation of the European Community Sixth Framework Programme (2002 to 2006) ⁽⁴⁾ (referred to as 'the rules for participation'), proposals for indirect RTD actions should be submitted under the terms of calls for proposals.

3. Natural or legal persons fulfilling the conditions stated in the rules for participation and that do not fall under any of the exclusion cases in the rules for participation or in Article 114(2) of the Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities ⁽⁵⁾ (referred to as 'the proposers') are invited to submit to the Commission proposals for indirect RTD actions subject to the conditions in the rules for participation and in the call concerned being fulfilled.

The conditions of participation of the proposers will be verified within the framework of the negotiation of the indirect RTD action. Before that however, proposers will have signed a declaration stating that they do not fall under any of the cases given by Article 93(1) of the Financial Regulation. They will also have given the Commission the information listed in Article 173(2) of the Commission Regulation (EC, Euratom) No 2342/2002, of 23 December 2002, laying down detailed rules for the implementation of Council Regulation (EC, Euratom) No 1605/2002 on the Financial Regulation applicable to the general budget of the European Communities ⁽⁶⁾.

⁽¹⁾ OJ L 232, 29.8.2002, p. 1.

⁽²⁾ OJ L 294, 29.10.2002, p. 1.

⁽³⁾ Commission Decision C(2002)4789, as modified by C(2003)577, C(2003)955, C(2003)1952, C(2003)3543, C(2003)3555, C(2003)4609, C(2003)5183, C(2004)433, C(2004)2002, C(2004)2727, C(2004)3324, C(2004)4178, C(2004)5286, C(2005)27, C(2005)961, and C(2005)2076, all decisions unpublished.

⁽⁴⁾ OJ L 355, 30.12.2002, p. 23.

⁽⁵⁾ OJ L 248, of 16.9.2002, p. 1.

⁽⁶⁾ OJ L 357, of 31.12.2002, p. 1.

The European Community has adopted an equal opportunities policy and, on this basis, women are particularly encouraged to either submit proposals for indirect RTD actions or participate in the submission of proposals for indirect RTD actions.

4. The Commission makes available to proposers guides for proposers relating to the calls which contain information on the preparation and the submission of a proposal for an indirect RTD action. The Commission also makes available Guidelines on Proposal Evaluation and Selection Procedures⁽¹⁾. These guides and guidelines, as well as the work programme and other information relating to the calls, can be obtained from the Commission via the following addresses:

European Commission
The FP6 Information Desk
Directorate General RTD
B-1049 Brussels
Internet address: <http://fp6.cordis.lu/lifescihealth/calls.cfm>

5. Proposals for indirect RTD actions are invited to be submitted only as an electronic proposal via the web-based Electronic Proposal Submission System (EPSS⁽²⁾). In exceptional cases, however, a co-ordinator may request permission from the Commission to submit on paper in advance of a call deadline. This should be done by writing to one of the following addresses:

European Commission
Timothy Hall
Directorate General RTD
CDMA 2/173
B-1049 Brussels
Email addresses:
rtd-genomics-biotec@cec.eu.int or,
rtd-diseases@cec.eu.int

The request must be accompanied by an explanation of why the exception is being sought. Proposers wishing to use paper submission take the responsibility for ensuring that such requests for exemption and the associated procedures are completed in time for them to meet the call deadline.

All proposals for indirect RTD actions must contain two parts: the forms (Part A) and the content (Part B).

Proposals for indirect RTD actions may be prepared off-line or on-line and submitted on-line. Part B of proposals for indirect RTD actions can only be submitted in PDF ('portable document format', compatible with Adobe Version 3 or higher with embedded fonts). Compressed ('zipped') files will be excluded.

The EPSS software tool (for off-line or on-line usage) is available via the Cordis website www.cordis.lu.

Proposals for indirect RTD actions that are submitted on-line and which are incomplete, illegible or contain viruses will be excluded.

Versions of proposals for indirect RTD actions submitted on a removable electronic storage medium (eg, CD-ROM, diskette), by email or by fax will be excluded.

Any proposal for indirect RTD actions that has been allowed to be submitted on paper and which is incomplete will be excluded.

Further details on the various proposal submission procedures are given in Annex J of the Guidelines on Proposal Evaluation and Selection Procedures.

6. Proposals for indirect RTD actions have to reach the Commission at the latest on the closure date and at the time specified in the call concerned. Proposals for indirect RTD actions arriving after this date and time will be excluded.

Proposals for indirect RTD actions not satisfying the conditions relating to the minimum number of participants indicated in the call concerned will be excluded.

This also applies regarding any additional eligibility criteria given in the work programme.

7. In the case of successive submissions of the same proposal for an indirect RTD action, the Commission will examine the last version received before the closure date and time specified in the call concerned.
8. If foreseen in the relevant call, proposals for indirect RTD actions could be evaluated in the framework of a future evaluation.
9. In all correspondence relating to a call (e.g. when requesting information, or submitting a proposal for an indirect RTD action), proposers are invited to cite the relevant call identifier.

⁽¹⁾ C(2003)883 of 27/3/2003, as last modified by C(2004)1855 of 18.5.2004.

⁽²⁾ The EPSS is a tool to assist proposers to develop and submit their proposals electronically.

ANNEX 1

FP6-2005-LIFESCIHEALTH-6
Call information (Thematic call)

1. **Specific Programme:** 'Integrating and strengthening the European Research Area'
2. **Activity:** Priority thematic area of research 'Life sciences, genomics and biotechnology for health'.
3. **Call title:** Thematic call in the area of 'Life sciences, genomics and biotechnology for health'.
4. **Call identifier:** FP6-2005-LIFESCIHEALTH-6
5. **Date of publication:** 8 July 2005
6. **Closure date:** 9 November 2005 at 17.00 (Brussels local time).
7. **Total indicative budget:** EUR 381,6 million, broken down as follows:

Instrument (*)	EUR (millions)
IP or NOE	252,1 — 282,1
STREP or CA or area specific SSA	93,5 — 123,5
Strategic SSA across Thematic priority 1	6

(*) IP = Integrated project; NOE = Network of excellence; STREP = Specific targeted research project; CA = Coordination action; SSA = Specific support action

8. Areas called and Instruments:

Proposals are invited in the following areas, which are described using activity codes only. For the full title and definition of topic, applicants must refer to the Work Programme (Section 1.3 Technical Content). The evaluation of proposals will be based on the full definition of topic as described in the Work Programme. For the topic the instrument to be used is indicated.

(i) ***Advanced genomics and its applications for health***

(a) *Fundamental knowledge and basic tools for functional genomics in all organisms*

Topic Ref.	Instrument
Gene expression and proteomics	
LSH-2005-1.1.1-1	IP
Structural genomics	
LSH-2005-1.1.2-1	IP
Comparative genomics and population genetics	
LSH-2005-1.1.3-1	IP
LSH-2005-1.1.3-2	IP
LSH-2005-1.1.3-3	IP

Topic Ref.	Instrument
Bioinformatics	
Multidisciplinary functional genomics approaches to basic biological processes	
LSH-2005-1.1.5-1	IP
LSH-2005-1.1.5-2	IP
Across the area	
LSH-2005-1.1.0-1	CA
LSH-2005-1.1.0-2	SSA

(b) *Application of knowledge and technologies in the field of genomics and biotechnology for health*

Topic Ref.	Instrument
Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches	
LSH-2005-1.2.1-1	IP
LSH-2005-1.2.1-2	STREP
Development of new diagnostics	
LSH-2005-1.2.2-1	IP
LSH-2005-1.2.2-2	STREP
LSH-2005-1.2.2-3	STREP
Development of new in vitro tests to replace animal experimentation	
LSH-2005-1.2.3-1	IP
LSH-2005-1.2.3-2	SSA
LSH-2005-1.2.3-3	SSA
Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies	
LSH-2005-1.2.4-1	IP
LSH-2005-1.2.4-2	IP
LSH-2005-1.2.4-3	STREP
LSH-2005-1.2.4-4	STREP
LSH-2005-1.2.4-5	STREP
LSH-2005-1.2.4-6	STREP
Innovative research in post-genomics, which has high potential for application	
LSH-2005-1.2.5-1	IP
LSH-2005-1.2.5-2	IP
LSH-2005-1.2.5-3	STREP

(ii) **Combating major diseases**(a) *Application-orientated genomic approaches to medical knowledge and technologies*

Topic Ref.	Instrument
General	
LSH-2005-2.1.0-1	STREP
Combating, cardiovascular disease, diabetes and rare diseases	
LSH-2005-2.1.1-1	IP
LSH-2005-2.1.1-2	NoE
LSH-2005-2.1.1-3	STREP
LSH-2005-2.1.1-4	STREP
LSH-2005-2.1.1-5	IP
LSH-2005-2.1.1-6	STREP
LSH-2005-2.1.1-7	NoE
LSH-2005-2.1.1-8	STREP
LSH-2005-2.1.1-9	STREP
Combating resistance to antibiotics and other drugs	
LSH-2005-2.1.2-1	IP
LSH-2005-2.1.2-2	STREP
LSH-2005-2.1.2-3	SSA
Studying the brain and combating diseases of the nervous system	
LSH-2005-2.1.3-1	IP
LSH-2005-2.1.3-2	IP
LSH-2005-2.1.3-3	STREP
LSH-2005-2.1.3-4	STREP
LSH-2005-2.1.3-5	SSA
Studying human development and the ageing process	
LSH-2005-2.1.4-1	NoE
LSH-2005-2.1.4-2	SSA

(b) *Combating cancer*

Topic Ref.	Instrument
LSH-2005-2.2.0-1	IP
LSH-2005-2.2.0-2	STREP
LSH-2005-2.2.0-3	STREP
LSH-2005-2.2.0-4	STREP
LSH-2005-2.2.0-5	STREP
LSH-2005-2.2.0-6	SSA

(c) *Confronting the major communicable diseases linked to poverty*

Topic Ref.	Instrument
LSH-2005-2.3.0-1	NoE
LSH-2005-2.3.0-2	NoE
LSH-2005-2.3.0-3	IP
LSH-2005-2.3.0-4	STREP
LSH-2005-2.3.0-5	STREP
LSH-2005-2.3.0-6	SSA/CA
LSH-2005-2.3.0-7	SSA/CA
LSH-2005-2.3.0-8	SSA/CA
LSH-2005-2.3.0-9	SSA/CA

SSAs across Thematic Priority 1

Topic Ref.	Instrument
LSH-2005-3-1	SSA
LSH-2005-3-2	SSA
LSH-2005-3-3	SSA
LSH-2005-3-4	SSA
LSH-2005-3-5	SSA
LSH-2005-3-6	SSA
LSH-2005-3-7	SSA
LSH-2005-3-8	SSA
LSH-2005-3-9	SSA
LSH-2005-3-10	SSA
LSH-2005-3-11	SSA
LSH-2005-3-12	SSA

9. Minimum number of participants ⁽¹⁾:

Instrument	Minimum number of participants
IP, NoE, STREP and CA	3 independent legal entities from 3 different MS or AS, with at least 2 MS or ACC.
SSA	1 legal entity from a MS or AS.

⁽¹⁾ MS = Member States of the EU; AS (incl. ACC) = Associated States; ACC = Associated candidate countries.
Any legal entity established in a Member State or Associated State and which is made up of the requested number of participants may be the sole participant in an indirect action.

10. **Restriction on participation:** None.
 11. **Consortia agreements:**
 - Participants in IP and NOE are required to conclude a consortium agreement.
 - Participants in STREP, CA and SSA resulting from this call are encouraged, but not required, to conclude a consortium agreement.
 12. **Evaluation procedure:**
 - The evaluation shall follow a single stage procedure;
 - Proposals will not be evaluated anonymously;
 - The evaluation process may involve 'remote' evaluation of proposals;
 - Applicants may be invited to discuss their proposal.
 13. **Evaluation criteria:** See Annex B of the work programme for the applicable criteria (including their individual weights and thresholds and the overall threshold) per instrument.
 14. **Indicative evaluation and contractual timetable:**
 - Evaluation results: expected to be available some 4 months after the closure date
 - Contract signature: it is estimated that the first contracts related to this call will come into force by the end of 2006.
-

ANNEX 2

FP6-2005-LIFESCIHEALTH-7

Call information (STREPs dedicated to SMEs)

1. **Specific Programme:** 'Integrating and strengthening the European Research Area'
2. **Activity:** Priority thematic area of research 'Life sciences, genomics and biotechnology for health'.
3. **Call title:** Call for STREPs dedicated to SMEs in the area of 'Life sciences, genomics and biotechnology for health'.
4. **Call identifier:** FP6-2005-LIFESCIHEALTH-7
5. **Date of publication:** 8 July 2005
6. **Closure date:** 9 November 2005 at 17.00 (Brussels local time).
7. **Total indicative budget:** EUR 171 million, broken down as follows:

Instrument (*)	EUR (millions)
STREP	171

(*) STREP = Specific targeted research project.

8. Areas called and Instruments:

Proposals are invited in the following areas, which are described using activity codes only. For the full titles and definition of areas, applicants must refer to the Work Programme (Section 1.3 Technical Content). The evaluation of proposals will be based on the full definition as described in the Work Programme.

(i) *Advanced genomics and its applications for health*(a) *Fundamental knowledge and basic tools for functional genomics in all organisms*

Topic Ref.	Instrument
Across the area	
LSH-2005-1.1.0-3	STREP

(b) *Application of knowledge and technologies in the field of genomics and biotechnology for health*

Topic Ref.	Instrument
Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches	
LSH-2005-1.2.1-3	STREP
Development of new diagnostics	
LSH-2005-1.2.2-4	STREP
Development of new in vitro tests to replace animal experimentation	
LSH-2005-1.2.3-4	STREP
Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies	
LSH-2005-1.2.4-7	STREP
Innovative research in post-genomics, which has high potential for application	
LSH-2005-1.2.5-4	STREP

(ii) **Combating major diseases**(a) *Application-orientated genomic approaches to medical knowledge and technologies*

Topic Ref.	Instrument
Combating, cardiovascular disease, diabetes and rare diseases	
LSH-2005-2.1.1-10	STREP
LSH-2005-2.1.1-11	STREP
LSH-2005-2.1.1-12	STREP
Combating resistance to antibiotics and other drugs	
LSH-2005-2.1.2-4	STREP
LSH-2005-2.1.2-5	STREP
Studying the brain and combating diseases of the nervous system	
LSH-2005-2.1.3-6	STREP
LSH-2005-2.1.3-7	STREP
LSH-2005-2.1.3-8	STREP
LSH-2005-2.1.3-9	STREP
Studying human development and the ageing process	
LSH-2005-2.1.4-3	STREP

(b) *Combating cancer*

Topic Ref.	Instrument
LSH-2005-2.2.0-7	STREP
LSH-2005-2.2.0-8	STREP
LSH-2005-2.2.0-9	STREP

(c) *Confronting the major communicable diseases linked to poverty*

Topic Ref.	Instrument
LSH-2005-2.3.0-10	STREP
LSH-2005-2.3.0-11	STREP
LSH-2005-2.3.0-12	STREP

9. **Minimum number of participants⁽¹⁾:**

Instrument	Minimum number of participants
STREP	3 independent legal entities from 3 different MS or AS, with at least 2 MS or ACC.

⁽¹⁾ MS = Member States of the EU; AS (incl. ACC) = Associated States; ACC = Associated candidate countries.
Any legal entity established in a Member State or Associated State and which is made up of the requested number of participant may be the sole participant in an indirect action.

10. **Restriction on participation:** All consortia should aim at having 30-50 % of the requested EC contribution budget going to SMEs.
 11. **Consortia agreements:**
Participants in STREP resulting from this call are encouraged, but not required, to conclude a consortium agreement.
 12. **Evaluation procedure:**
The evaluation shall follow a single stage procedure;
Proposals will not be evaluated anonymously;
The evaluation process may involve 'remote' evaluation of proposals;
Applicants may be invited to discuss their proposal.
 13. **Evaluation criteria:** See Annex B of the work programme for the applicable criteria (including their individual weights and thresholds and the overall threshold) per instrument.
 14. **Indicative evaluation and contractual timetable:**
 - Evaluation results: expected to be available some 4 months after the closure date
 - Contract signature: it is estimated that the first contracts related to this call will come into force by the end of 2006.
-